2022 World Conference on Lung Cancer (Posters)-P1.09-02. Real-world Clinical Characteristics and Treatment Patterns of METExon 14 Skipping Mutation in Advanced/Metastatic NSCLC

P1.09-02. Real-world Clinical Characteristics and Treatment Patterns of METExon 14 Skipping Mutation in Advanced/Metastatic NSCLC

Back to course

Pdf Summary

This study investigated the clinical characteristics and treatment patterns of patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring the MET exon 14 skipping mutation (METex14) compared to MET wild type (METwt) using real-world data from a US database. The study included 138 patients with METex14 and 5,162 patients with METwt. <br /><br />The results showed that patients with METex14 were typically older, female, had non-squamous cell carcinoma, and higher expression of programmed death-ligand 1 (PD-L1) compared to METwt. The prevalence of high tumor mutation burden (TMB-H) was lower in patients with METex14. There were no significant differences between the two cohorts in Eastern Cooperative Oncology Group (ECOG) performance status, stage at initial diagnosis, or sites of metastasis.<br /><br />In terms of treatment patterns, chemotherapy was the most common first-line (1L) treatment for both cohorts, followed by immunotherapy (IO). Multikinase inhibitors (MKis) were used in a small percentage of patients with METex14 as 1L, 2L, and 3L treatment. There was a decrease in the use of IO chemotherapy in 1L for the METex14 cohort, likely due to an increase in the use of MKis.<br /><br />The study has provided insights into the clinical characteristics and treatment patterns of patients with METex14 NSCLC in a real-world setting. These findings may help inform treatment decisions for patients with this specific mutation. Further research is needed to understand the prognostic impact of METex14 in the current treatment landscape.

Asset Subtitle

Xiuning Le, United States

Meta Tag

Speaker Xiuning Le, United States

Topic Global Health, Health Services Research, and Health Economics - Support to Patients and Staff

Keywords

METex14

METwt

NSCLC

PD-L1

TMB-H

chemotherapy

immunotherapy

MKis

real-world data

treatment patterns